Feb. 18, 2009
Image of a retina affected by sympathetic ophthalmia (Photo, upper right): In the eye disease sympathetic ophthalmia, areas of the retina that have become scarred due to inflammation appear in yellow, while normal areas appear red-orange. Credit: University of Iowa
Image of the Retisert device (Photo, lower right): A surgically implantable device called a Retisert is dwarfed by a dime in this comparison photo. When inserted into the endangered eye of a person with the rare condition sympathetic ophathalmia, the plastic tab slowly releases a steroid that helps stem the effects of an overactive immune system, a problem that could cause blindness. Previously, doctors had to use whole-body drugs with serious side effects to "shut down" a person's entire immune system to stop the attack on the eye. Credit: Courtesy of Bausch and Lomb.
New surgical implant tested at UI prevents total blindness
A work accident leaves a woman blind in one eye. As she copes with the loss, within months the vision in the other, previously uninjured eye begins to blur, and the eye becomes red and inflamed.
The rare eye condition, known as sympathetic ophthalmia, occurs when vision is lost in one eye through injury or multiple surgeries, and the body's overactive immune system attacks the remaining healthy eye. Left untreated, a person can become completely blind.
However, University of Iowa ophthalmologists and colleagues have tested and are now using a surgical implant called Retisert to prevent complete vision loss and eliminate dependence on systemic, or whole-body, immunosuppression. Before use of the surgical technique, doctors had to "shut down" a person's entire immune system to stop the attack on the remaining good eye.
"Until recently, the primary treatment option for sympathetic ophthalmia was nonsurgical and involved high doses of oral steroids followed by oral immunosuppressive medication to preserve vision in a patient's remaining eye," said Vinit Mahajan, M.D., Ph.D., assistant professor of ophthalmology and visual sciences at the UI Roy J. and Lucille A. Carver College of Medicine and a retinal surgeon with UI Hospitals and Clinics.
"But this treatment, similar to organ transplantation cases, subjects patients to life-long use of immunosuppressive drugs that have serious side effects such as osteoporosis, weight gain, potentially life-threatening infection and liver or kidney damage," he added.
The new Retisert treatment involves the surgical implantation into the endangered eye of a small plastic tab that contains a slow-release steroid called fluocinoloe acetonide. The insert provides immunosuppression only to the endangered eye, not other body parts. It lasts for about two-and-a-half years and then can be replaced.
Along with UI retinal surgeons James Folk, M.D., professor of ophthalmology, and Karen Gehrs, M.D., clinical associate professor of ophthalmology, Mahajan published a retrospective paper online in January in the journal Ophthalmology that documents the successful use of Retisert to treat eight patients with sympathetic ophthalmia.
The device previously was studied in approximately 300 individuals who had a different immune system inflammation of the eye. The UI-led sympathetic ophthalmia study found that with Retisert, the eight patients reduced or eliminated use of systemic medications to control inflammation. While two patients needed to resume using an oral immunosuppressive, vision improved or remained stable in all eight patients.
"Using Retisert, we are stabilizing vision in patients with sympathetic ophthalmia and getting them off the heavy-duty immunosuppressive medications," Mahajan said. "Patients had been willing to put up with the serious side effects of systemic immunosuppression because if they lost vision in their remaining good eye, it would be totally life-altering. With Retisert, we can save the eye, and the side effects are limited to treatable risks of high pressure or cataracts in the eye."
While each implant costs approximately $20,000, their use appears to be less expensive over the long run compared to systemic immunosuppressive drugs and the required frequent hospital visits.
"If you add up the total number of patient visits, costs of lab tests and the costs of the immunosuppressive drugs, the $20,000 for the device is cheaper," Mahajan said.
Mahajan and colleagues are reaching out to retinal surgeons nationwide to make them aware of this new treatment option for patients with sympathetic ophthalmia.
In addition to the UI and the Wills Eye Institute, the retrospective study involved researchers at the University of Illinois Eye and Ear Infirmary and Sentro Oftalmogico Jose Rizal at the University of the Philippines.
The study was supported in part by a grant from Research to Prevent Blindness. In addition, Folk is the Judith (Gardner) and Donald H. Beisner, M.D., Professor for Vitreoretinal Diseases and Surgery.
PHOTOS: Higher-res version may be available on request to the media contact. V. Mahajan: http://webeye.ophth.uiowa.edu/dept/BIOGRAPH/mahajanPX.htm
STORY SOURCE: University of Iowa Health Care Media Relations, 5137 Westlawn, Iowa City, Iowa 52242-1178
MEDIA CONTACT: Becky Soglin, 319-335-6660, email@example.com